SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Inhibrx, Inc.
(Nasdaq: INBX), a biotechnology company with four clinical programs
in development and an emerging pre-clinical pipeline, announced
today that the Company will be presenting three poster
presentations at the Society for Immunotherapy of Cancer's (SITC)
annual meeting, to be held in Washington,
D.C. and in a virtual platform, on November 10-14, 2021.
"We are excited to share some of the preclinical data related
to our clinical candidates, INBRX-105 and INBRX-106, which inform
the selection of pharmacodynamic biomarkers, dosing and clinical
strategy," said Brendan
Eckelman, Ph.D., Inhibrx Co-founder and Chief Scientific
Officer.
"Additionally, we will be introducing the first emerging
pipeline candidate from our targeted cytokine platform, INBRX-121,
which specifically expands and enhances the cytotoxic capacity of
NK cells."
Poster Presentation Details:
Title: INBRX-106: A novel hexavalent anti-OX40 agonist for the
treatment of solid tumors
Lead Author: Emily Rowell, Ph.D.
Category: Novel Single-Agent Immunotherapies
Abstract: 856
Session Date & Time: ePoster on display beginning Friday, November 12th; 7:00 a.m. EST
Title: INBRX-105- Key pharmacokinetic and pharmacodynamic
parameters that correlate with the anti-tumor activity of a
bispecific PD-L1 conditional 4-1BB agonist
Lead Author: Heather Kinkead,
Ph.D.
Category: Biomarkers, Immune Monitoring, and Novel Technologies
Abstract: 12
Session Date & Time: Saturday, November
13th; 7:00 a.m.- 8:30 p.m.
EST
Title: INBRX-121 is an NKp46-targeted detuned IL-2 with
antitumor activity as a monotherapy or in combination with multiple
cancer immunotherapy modalities
Lead Author: Florian J. Sulzmaier, Ph.D.
Category: Immune-Stimulants and Immune Modulators
Abstract: 722
Session Date & Time: Saturday, November
13th; 7:00 a.m.- 8:30 p.m.
EST
The scientific posters will be accessible through the following
link on the investors section of Inhibrx's website at
https://inhibrx.investorroom.com/events-and-presentations.
About Inhibrx, Inc.
Inhibrx is a clinical-stage biotechnology company focused on
developing a broad pipeline of novel biologic therapeutic
candidates in oncology and orphan diseases. Inhibrx utilizes
diverse methods of protein engineering to address the specific
requirements of complex target and disease biology, including its
proprietary sdAb platform. Inhibrx has collaborations with 2seventy
bio (formerly bluebird bio), Bristol-Myers Squibb and Chiesi. For
more information, please visit www.inhibrx.com.
Investor and Media Contact:
Kelly Deck
CFO
kelly@inhibrx.com
858-795-4260
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-presentations-at-sitc-2021-301415015.html
SOURCE Inhibrx Inc.